v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development (including stock-based compensation expense of $0.9 million and $0.5 million for three months ended March 31, 2026 and 2025, respectively) $ 21,431 $ 10,534
General and administrative (including stock-based compensation expense of $1.7 million and $1.1 million for the three months ended March 31, 2026 and 2025, respectively) 6,112 5,651
Total operating expenses 27,543 16,185
Loss from operations (27,543) (16,185)
Other income (expense), net    
Interest income, net 2,133 3,100
Research and development tax credit 567 0
Other expense, net (46) (9)
Total other income, net 2,654 3,091
Loss before income taxes (24,889) (13,094)
Income tax provision 519 31
Net loss (25,408) (13,125)
Other comprehensive income (loss), net of tax:    
Foreign currency translation adjustment 15 0
Unrealized (loss) gain on available-for-sale securities (252) 192
Comprehensive loss $ (25,645) $ (12,933)
Net loss per share, basic $ (10.34) $ (5.65)
Net loss per share, diluted $ (10.34) $ (5.65)
Weighted-average common shares outstanding, basic 2,456,766 2,323,724
Weighted-average common shares outstanding, diluted 2,456,766 2,323,724